Patent application number | Description | Published |
20080292655 | ENHANCEMENT OF THE IMMUNE RESPONSE FOR VACCINE AND GENE THERAPY APPLICATIONS - Expression cassettes are provided comprising a promoter operably linked to a nucleic acid molecule which, when transcribed in vivo, forms double-stranded RNA that induces the production of interferon. Expression cassettes also are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, forms a ribozyme or antisense RNA molecule that stimulates an immune response. In addition, expression cassettes are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, stimulates apoptosis. Finally, gene delivery vectors are provided which contain such expression cassettes, host cells containing the gene delivery vectors, and methods of utilizing the expression cassettes, gene delivery vectors, and host cells. | 11-27-2008 |
20100055128 | METHOD FOR THE PURIFICATION OF ALPHAVIRUS REPLICON PARTICLES - Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. in one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics. | 03-04-2010 |
20100068230 | MODIFIED FREE-LIVING MICROBES, VACCINE COMPOSITIONS AND METHODS OF USE THEREOF - Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases. | 03-18-2010 |
20100129406 | HOLIN-ENHANCED VACCINES AND REAGENTS, AND METHODS OF USE THEREOF - The invention provides | 05-27-2010 |
20100233212 | METHODS AND COMPOSITIONS USING LISTERIA FOR ENHANCING IMMUNOGENICITY BY PRIME BOOST - Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active | 09-16-2010 |
20100266631 | Compositions and Methods for Generating an Immune Response Utilizing Alphavirus-Based Vector Systems - Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems and Alphavirus replicon particles for introducing heterologous sequences into cells for generating immune responses. | 10-21-2010 |
20110201092 | LISTERIA ATTENUATED FOR ENTRY INTO NON-PHAGOCYTIC CELLS, VACCINES COMPRISING THE LISTERIA, AND METHODS OF USE THEREOF - The present invention provides | 08-18-2011 |
20120114693 | NUCLEIC ACID MUCOSAL IMMUNIZATION - Mucosal delivery of antigens using, for example, a replication-defective gene delivery vehicle, particularly replication-defective alphavirus vectors and particles, is described. Also described are compositions comprising a mucosal adjuvant and one or more antigens derived from HIV. Also provided is the use of these gene delivery vehicles in inducing mucosal, local, and/or systemic immune responses following mucosal immunization regimes. | 05-10-2012 |
20120121643 | Engineered listeria and methods of use thereof - The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes. | 05-17-2012 |
20120231526 | Method for the Purification of Alphavirus Replicon Particles - Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. In one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics | 09-13-2012 |
20120263754 | Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines - Provided herein are methods for inducing a specific immune response in a subject by administering to the subject an immunogenic composition comprising a recombinant expression vector, or a vector particle comprising the recombinant expression vector, which vector comprises a polynucleotide sequence that encodes an immunogen of interest. The methods further comprise administering an adjuvant composition either concurrently or sequentially with the immunogenic composition. | 10-18-2012 |
20120328655 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR INDUCING HUMORAL AND CELLULAR IMMUNE RESPONSES - Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial. | 12-27-2012 |
20140186387 | SIGNAL PEPTIDE FUSION PARTNERS FACILITATING LISTERIAL EXPRESSION OF ANTIGENIC SEQUENCES AND METHODS OF PREPARATION AND USE THEREOF - The present invention provides nucleic acids, expression systems, and vaccine strains which provide efficient expression and secretion of antigens of interest into the cytosol of host cells, and elicit effective CD4 and CD8 T cell responses by functionally linking Listerial or other bacterial signal peptides/secretion chaperones as N-terminal fusion partners in translational reading frame with selected recombinant encoded protein antigens. These N-terminal fusion partners are deleted (either by actual deletion, by mutation, or by a combination of these approaches) for any PEST sequences native to the sequence, and/or for certain hydrophobic residues. | 07-03-2014 |
20140205653 | COMPOSITIONS COMPRISING CYCLIC PURINE DINUCLEOTIDES HAVING DEFINED STEREOCHEMISTRIES AND METHODS FOR THEIR PREPARATION AND USE - It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers. | 07-24-2014 |
20140341976 | COMPOSITIONS AND METHODS FOR INHIBITING "STIMULATOR OF INTERFERON GENE" -DEPENDENT SIGNALLING - The present invention provides cyclic-di-nucleotide (CDN) compounds that inhibit signaling at a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides which inhibit STING-dependent TBK1 activation and the resulting production of type I interferon. | 11-20-2014 |
20150056224 | COMPOSITIONS AND METHODS FOR ACTIVATING STIMULATOR OF INTERFERON GENE-DEPENDENT SIGNALLING - The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2′,5′,2′,5′ and 2′,5′,3′,5′ CDNs, and preferably Rp,Rp stereosiomers thereof. | 02-26-2015 |